Equity Analyst, LightStream Research

Shifara Samsudeen, ACMA, CGMA

A chartered management accountant with more than 10 years of rich experience in investment research and financial analysis. Worked as an equity analyst for one of the world's largest asset managers with USD2.5trn in AUM covering numerous sectors including chemicals, retail, tech, autos, telco, real-estate and banks, globally. Experienced in fundamental equity research, industry research, commodity studies, forensic accounting, and due diligence reviews.

Equity Analyst

Lepu Biopharma IPO: No Monetisation Timeline in Sight

GOGOX IPO: Overseas Business Maintains Growth but China Biz Under Pressure Due to Competition

Broncus Holdings IPO: Say No to Lung Diseases

Shanghai Heartcare IPO: DCF Offers Decent Upside but Mind the Ongoing Lawsuit with Medtronic

Zylox-Tonbridge IPO: Comprehensive Coverage, Proven Marketing and Core Products Show Good Potential

Battle Lines Drawn As BABA Builds Out First/Last-Mile Capacity; But Who Will Fund 75+ Bn CNY CapEx?

Long-Short Analysis on Japan, Asia and the World

LightStream Research

LightStream conducts quantitatively rigorous and data-driven analysis with a focus on Japan and Asia.

We consistently cover the Tech, Consumer and Industrial sectors, and provide ECM and Events coverage more broadly.

We supplement traditional qualitative insights from company relationships with a robust quantitative foundation that examines as much historical data as is available.
We further refine the accuracy of our insights and calls through the use of alternative data to flesh out current trends, and through a valuation framework that emphasises non-superficial peer group selection and a proper attempt to understand the metrics and changes that have driven security valuations in the past.

Equity Capital Markets

Shanghai Bio-Heart Biological Technology / Equity Capital Markets

Shanghai Bio-Heart Biological Technology (2185 HK)

<ul>
<li>Bio-Heart is a leading innovative interventional cardiovascular device company focused on two therapies for the treatment of coronory/peripheral artery diseases and uncontrolled and resistant hypertension.</li>
<li>Bio-Heart is a leading innovative interventional cardiovascular device company focused on two therapies for the treatment of coronory/peripheral artery diseases and uncontrolled and resistant hypertension.</li>
<li>The company has filed for an IPO on the HKEx to raise about US$200-300m and the company’s application has been approved.</li>
</ul>


Bio-Heart is a leading innovative interventional cardiovascular device company focused on two therapies for the treatment of coronory/peripheral artery diseases and uncontrolled and resistant hypertension.
Bio-Heart is a leading innovative interventional cardiovascular device company focused on two therapies for the treatment of coronory/peripheral artery diseases and uncontrolled and resistant hypertension.
The company has filed for an IPO on the HKEx to raise about US$200-300m and the company’s application has been approved.


Shanghai Bio-Heart IPO: Strong Product Candidates but For Those Willing to Wait